secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2023-11-09T23:59:59+00:00
Accession:  0001628280-23-038030
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo eliminates $35M debt, Q3 net loss $5.2M; cash $10.2M; divests 800 series for up to $45M
--------------------------------------------------------------------------------

- Paid off remaining $14.3M of $35M debt to Horizon Technology; all loan obligations satisfied.
- Divested AVTX-800 series to AUG for up to $45M in milestone payments; pipeline focused on immunology.
- Q3 2023 net loss $5.2M ($0.11 diluted loss) vs net income $3.2M a year ago; revenue fell to $236K from $14.9M.
- Cash and cash equivalents $10.2M at Sept 30, 2023; raised $46.2M net from equity financings in 9 months.
- Advancing quisovalimab (anti-LIGHT mAb) toward planned ulcerative colitis trial; AVTX-008 BTLA agonist progressing to IND.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/0001628280-23-038030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000162828023038030/avtx-20231109.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-038030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer